Timing of Chemotherapy After MammoSite Radiation Therapy System Breast Brachytherapy: Analysis of the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial

• Published in: International journal of radiation oncology, biology, physics Vol. 72; no. 5; pp. 1441 - 1448
• Main Authors: Haffty, Bruce G., M.D, Vicini, Frank A., M.D, Beitsch, Peter, M.D, Quiet, Coral, M.D, Keleher, Angela, M.D, Garcia, Delia, M.D, Snider, Howard, M.D, Gittleman, Mark, M.D, Zannis, Victor, M.D, Kuerer, Henry, M.D, Whitacre, Eric, M.D, Whitworth, Pat, M.D, Fine, Richard, M.D, Keisch, Martin, M.D
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2008
• Subjects: Accelerated partial breast irradiation; Adult; Aged; Antineoplastic Agents - therapeutic use; BRACHYTHERAPY; Brachytherapy - methods; Brachytherapy - statistics & numerical data; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Breast-conserving surgery; CARCINOMAS; CHEMOTHERAPY; Combined Modality Therapy; Cosmesis; Female; Hematology, Oncology and Palliative Medicine; Humans; IRRADIATION; MAMMARY GLANDS; Mastectomy, Segmental - methods; Middle Aged; Neoplasm Staging; PATIENTS; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; Reconstructive Surgical Procedures; Registries; Societies, Medical; SURGERY; Surgery, Plastic; Time Factors; Timing; Treatment Outcome; United States; United States; Accelerated partial breast irradiation; Cosmesis; Chemotherapy; Timing; Breast-conserving surgery
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2008.02.070

Purpose To evaluate cosmetic outcome and radiation recall in the American Society of Breast Surgeons registry trial, as a function of the interval between accelerated partial breast irradiation (APBI) and initiation of chemotherapy (CTX). Methods and Materials A total of 1440 patients at 97 institutions participated in this trial. After lumpectomy for early-stage breast cancer, patients received APBI (34 Gy in 10 fractions) with MammoSite RTS brachytherapy. A total of 148 patients received CTX within 90 days of APBI. Cosmetic outcome was evaluated at each follow-up visit and dichotomized as excellent/good or fair/poor. Results Chemotherapy was initiated at a mean of 3.9 weeks after the final MammoSite procedure and was administered ≤3 weeks after APBI in 54 patients (36%) and >3 weeks after APBI in 94 patients (64%). The early and delayed groups were well balanced with respect to multiple factors that may impact on cosmetic outcome. There was a superior cosmetic outcome in those receiving chemotherapy >3 weeks after APBI (excellent/good in 72.2% at ≤3 weeks vs. excellent/good in 93.8% at >3 weeks; p = 0.01). Radiation recall in those receiving CTX at ≤3 weeks was 9 of 50 (18%), compared with 6 of 81(7.4%) in those receiving chemotherapy at >3 weeks ( p = 0.09). Conclusion The majority of patients receiving CTX after APBI have excellent/good cosmetic outcomes, with a low rate of radiation recall. Chemotherapy initiated >3 weeks after the final MammoSite procedure seems to be associated with a better cosmetic outcome and lower rate of radiation recall. An excellent/good cosmetic outcome in patients receiving CTX after 3 weeks was similar to the cosmetic outcome of the overall patient population who did not receive CTX.